65,437 trials
Diabetic Gastroparesis
Primary: Gastroparesis Symptom Assessment (GSA), a Patient Reported Outcome Measure — -0.751; -0.657 score on a scale — p=0.597
Metastasis Spine · Metastasis to Bone
Primary: Change of Worst Pain Score: Thoracic/Lumbar Spine RF Ablation — -4.1 units on a scale — p=<0.0001
Lupus Nephritis
Primary: Double-blind Period: Percentage of Participants With Primary Efficacy Renal Response (PERR) at Week 104 — 32.3; 43.0 Percentage of participants — p=0.0311
Diabetes · Diabetes Mellitus, Type 2
Primary: Time to Inadequate Glycaemic Control — 108.9; 64.9 Weeks — p=<.0001
Breast Neoplasm · Lesion
Primary: Patients With Successful Placement of the Radiofrequency Tag Under Radiographic Guidance Confirmed by Mammography — 50 Participants
Breast Cancer
Primary: Number of Participants Offered and Screened for Distress — 596; 3 Participants
Lung Cancer
Primary: Thoroughness of Invasive Staging, Multidisciplinary (MD) vs Serial Care (SC) — 108; 168; 70; 180 Participants — p=0.0007
Open Angle Glaucoma
Primary: Percentage of Participants Achieving Intraocular Pressure Reduction Thresholds — 21; 21; 1; 3 Participants
Hypothermia · Rewarming
Primary: Time to Normothermia — 4.4 hours
Dizziness
Primary: Modified Clinical Test of Sensory Integration for Balance (mCTSIB) — 115.98; 97.4; 110.15; 107.23 seconds — p=.640
Depression
Primary: Montgomery-Asberg Depression Rating Scale — 13.4; 14.2 score on a scale
Chronic Low Back Pain
Primary: Pain Severity: Visual Analog Scale — 7.26; 7.75; 7.8; 7.62 score on a scale
Pregnant Women · Pain · Hypotension
Primary: Time to Regression of Motor Block — 180; 130 minutes
NSCLC
Primary: Number of Participants Who Were Previously Treated With Dacomitinib on the Parent Study in Japan and Who Got Access to Dacomitinib in This Extension Study — 7 Participants
Migraine, With or Without Aura
Primary: Number of Participants With SAEs and AEs Leading to Discontinuation During the Treatment Period — 664; 315; 109; 108 Participants